BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32037523)

  • 1. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
    Zaal EA; Wu W; Jansen G; Zweegman S; Cloos J; Berkers CR
    Cancer Metab; 2017; 5():7. PubMed ID: 28855983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Zhang X; Bai W
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting phosphoglycerate dehydrogenase in multiple myeloma.
    Elsaadi S; Steiro I; Abdollahi P; Vandsemb EN; Yang R; Slørdahl TS; Rø TB; Menu E; Sponaas AM; Børset M
    Exp Hematol Oncol; 2021 Jan; 10(1):3. PubMed ID: 33397437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
    Yin L; Kufe T; Avigan D; Kufe D
    Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
    Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
    Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
    Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
    Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.
    Wang J; Zeng L; Wu N; Liang Y; Jin J; Fan M; Lai X; Chen ZS; Pan Y; Zeng F; Deng F
    Drug Resist Updat; 2023 Sep; 70():100985. PubMed ID: 37423117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
    Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
    Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
    Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
    J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib.
    Łuczkowska K; Kulig P; Baumert B; Machaliński B
    Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
    Xia J; He Y; Meng B; Chen S; Zhang J; Wu X; Zhu Y; Shen Y; Feng X; Guan Y; Kuang C; Guo J; Lei Q; Wu Y; An G; Li G; Qiu L; Zhan F; Zhou W
    Mol Oncol; 2020 Apr; 14(4):763-778. PubMed ID: 31955515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.